PBTZ 169Alternative Names: PBTZ169
Latest Information Update: 06 Feb 2017
$50 / €47 *
At a glance
- Originator A. N. Bach Institute of Biochemistry; Ecole Polytechnique Federale de Lausanne.
- Developer Ecole Polytechnique Federale de Lausanne.; NEARMEDIC
- Class Antituberculars
- Mechanism of Action Cell wall inhibitors; DprE1 protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Tuberculosis